ECO has entered into a research partnership with Imperial College London to assess veterinary applications for its novel saRNA platform technology. This is the next generation of RNA-delivered medicines with a broad range of potential applications in vaccines and other therapeutics, crucially at a lower cost than existing mRNA technologies. It adds to ECO’s pipeline and strategy to diversify the business alongside lead product Aivlosin, which we continue to believe will be transformative for the ....
